Metoclopramide Mercury Pharmaceuticals

Metoclopramide, the active ingredient in Metoclopramide Mercury Pharmaceuticals, is a dopamine D2 receptor antagonist presented as an injection solution for intramuscular and intravenous use. It treats nausea and vomiting, including post‑operative, chemotherapy‑induced, and gastroparesis, in adult patients.

GNH USA supplies Metoclopramide Mercury Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic pathways that trigger nausea and on gastrointestinal motility, making it useful for several emetic and motility disorders. - Nausea and vomiting: reduces frequency and severity of episodes. - Post‑operative nausea and vomiting: prevents and treats symptoms after surgery. - Chemotherapy‑induced nausea and vomiting: controls acute and delayed nausea. - Gastroparesis: enhances gastric emptying and improves symptoms. - Gastro‑oesophageal reflux disease (adjunct therapy): supports gastric motility as part of combination therapy.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Restlessness: agitation or inability to stay still. - Diarrhea: loose stools or increased bowel movements. - Headache: mild to moderate head pain. - Insomnia: difficulty falling or staying asleep. - Fatigue: general lack of energy.

Serious or Rare Side Effects: - Extrapyramidal reactions: muscle rigidity, dystonia, or tremor. - Tardive dyskinesia: persistent involuntary movements with long‑term use. - Neuroleptic malignant syndrome: life‑threatening fever and muscle breakdown. - Severe allergic reactions: anaphylaxis, rash, or swelling. - Depression or suicidal thoughts: mood changes requiring immediate attention. - Hyperprolactinemia: galactorrhea or menstrual disturbances.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for known risks. - Assess renal and hepatic function: adjust therapy if impairment is present. - Monitor for extrapyramidal symptoms: observe for muscle rigidity or abnormal movements. - Use with caution in the elderly: increased susceptibility to side effects. - Avoid prolonged use beyond 12 weeks: higher risk of tardive dyskinesia. - Contraindicated in known hypersensitivity: discontinue immediately if reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metoclopramide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive central nervous system depression. - MAO inhibitors: risk of hypertensive crisis. - CYP2D6 inhibitors (e.g., fluoxetine): increased metoclopramide plasma levels. - QT‑prolonging agents: potential additive cardiac risk.

Moderate Interactions (Monitor Closely): - Opioids: may enhance gastrointestinal effects. - Sedatives or hypnotics: increased drowsiness and CNS depression. - Anticholinergics: may diminish pro‑kinetic efficacy. - Alcohol: potentiates central nervous system depression.